Exact Sciences Corp Announces Imminent Completion of Merger with Abbott Laboratories

Key Highlights for Investors

• All regulatory approvals and clearances for the merger between Exact Sciences and Abbott Laboratories have been received.
• Exact Sciences shareholders approved the merger at a special meeting held on February 20, 2026.
• The merger is expected to close on March 23, 2026, subject to remaining closing conditions.
• This transaction could have a material impact on Exact Sciences’ business and share value.

Details of the Merger Agreement

On November 19, 2025, Exact Sciences Corporation (“Exact”), a leading provider in the medical laboratories sector, entered into an Agreement and Plan of Merger with Abbott Laboratories (“Abbott”), a global healthcare company. Under the agreement, “Badger Merger Sub I, Inc.,” a wholly owned subsidiary of Abbott, will merge with and into Exact, with Exact surviving as a wholly owned subsidiary of Abbott.

As of March 19, 2026, all necessary regulatory approvals and clearances to consummate the merger have been obtained. This includes antitrust and other required government consents, which are often crucial hurdles in significant healthcare sector mergers. The only steps remaining are the formal satisfaction or waiver of certain closing conditions as specified in the merger agreement.

Shareholders of Exact Sciences already expressed their support for the transaction during a special meeting on February 20, 2026. The company expects the merger to close on March 23, 2026, barring any unforeseen circumstances.

Potentially Price-Sensitive Information for Shareholders

• Shareholder Approval and Regulatory Clearance: Both of these major milestones have been achieved. The market typically reacts to such news, as it greatly increases the certainty of the transaction’s completion.
• Anticipated Transaction Close: The merger is expected to close imminently (March 23, 2026). This could lead to significant repricing of Exact Sciences’ shares as the company will become a wholly owned subsidiary of Abbott.
• Risks and Uncertainties: The company highlights the possibility of the merger not being completed if certain conditions are not satisfied or waived, or if unforeseen events occur. There are also risks of the merger agreement being terminated under certain conditions, which could require Exact to pay a termination fee. Competing offers, transaction costs, and potential negative impacts on the company’s relationships with employees, customers, and suppliers are also mentioned as risks.
• Forward-Looking Statements: The company notes that forward-looking statements in the communication are subject to substantial risks and uncertainties, including but not limited to the successful and timely completion of the transaction, possible litigation or regulatory actions, and the effects of the transaction’s announcement or pendency on Exact’s business and stock price.

Implications for Investors

This merger is likely to be a significant event for Exact Sciences shareholders. The anticipated closing date means shareholders may soon see their shares converted or otherwise impacted by the terms of the merger. Investors should be aware of the residual risks—if the deal fails to close, or if unexpected costs or issues arise, the share price could react negatively.

On the other hand, successful completion under the agreed terms could unlock value for shareholders, potentially resulting in a premium being paid by Abbott or a repositioning of the business as part of a global healthcare leader.

The company also stresses that it will not update forward-looking statements unless required by law, so investors should monitor for official announcements or regulatory filings up to and after the closing date.

Conclusion

The imminent completion of the merger between Exact Sciences and Abbott Laboratories represents a pivotal moment for the company and its shareholders. With all regulatory and shareholder approvals in place and a closing date set, this is a highly significant and price-sensitive development that could change the trajectory of Exact Sciences’ business and share value in the near term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should consult their own advisors and read all company filings before making any investment decisions. The company undertakes no obligation to update forward-looking statements except as required by law.

View EXACT SCIENCES CORP Historical chart here